Home Cart Sign in  
Chemical Structure| 844442-38-2 Chemical Structure| 844442-38-2

Structure of AT7519
CAS No.: 844442-38-2

Chemical Structure| 844442-38-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AT7519 is a pan-CDKs inhibitor with IC50 values of 47, 13, <10nM for CDK2/CyclinA, CDK5/p35 and CDK9/CyclinT, and modest activity against CDK1/CyclinB, CDK3/CyclinE, CDK4/CyclinD1 and CDK6/CyclinD3 with IC50 values of 210, 360, 100 and 170nM, respectively.

Synonyms: AT7519M

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AT7519

CAS No. :844442-38-2
Formula : C16H17Cl2N5O2
M.W : 382.24
SMILES Code : O=C(C1=NNC=C1NC(C2=C(Cl)C=CC=C2Cl)=O)NC3CCNCC3
Synonyms :
AT7519M
MDL No. :MFCD13184820

Safety of AT7519

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H320-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of AT7519

Hedgehog

Isoform Comparison

Biological Activity

Target
  • CDK5

    CDK5/p35, IC50:13 nM

  • CDK4

    CDK4/CyclinD1, IC50:100 nM

  • CDK2

    CDK2/CyclinA, IC50:47 nM

  • CDK6

    CDK6/CyclinD3, IC50:170 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Neutrophils from healthy volunteers 1 μM 6 hours AT7519 induced apoptosis in neutrophils from healthy volunteers within 6 hours PMC5284332
Neutrophils from ARDS patients 1 μM 13 hours AT7519 induced apoptosis in neutrophils from ARDS patients after 13 hours of culture, and by 20 hours, apoptosis was at a level equivalent to AT7519-treated healthy control cells, thus completely overriding the pro-survival phenotype PMC5284332
MYCN-amplified neuroblastoma cell lines 0.64 nmol/L – 10 μmol/L 72 hours To evaluate the killing effect of AT7519 on MYCN-amplified neuroblastoma cells, results showed that MYCN-amplified cells were more sensitive to AT7519 with a median LC50 value of 1.7 μmol/L PMC4645454
non-MYCN-amplified neuroblastoma cell lines 0.64 nmol/L – 10 μmol/L 72 hours To evaluate the killing effect of AT7519 on non-MYCN-amplified neuroblastoma cells, results showed that non-MYCN-amplified cells were less sensitive to AT7519 with a median LC50 value of 8.1 μmol/L PMC4645454
U87MG 0.4 µM 6, 12, 24 h AT7519 significantly inhibited the proliferation of U87MG cells and induced cell cycle arrest at G1 and G2 phases. PMC9829897
U251 0.4 µM 6, 12, 24 h AT7519 significantly inhibited the proliferation of U251 cells and induced cell cycle arrest at G1 and G2 phases. PMC9829897
GBM38 0.4 µM 48 h AT7519 significantly induced apoptosis in GBM38 cells. PMC9829897
GBM60 0.4 µM 48 h AT7519 significantly induced apoptosis in GBM60 cells. PMC9829897
MiaPaCa2 1 μM 72 hours AT7519 inhibited the viability of mt KRas-dependent cells with IC50 value of 0.45 ± 0.07 μM PMC8493485
L3.6pl 1 μM 72 hours AT7519 inhibited the viability of mt KRas-dependent cells with IC50 value of 0.29 ± 0.02 μM PMC8493485
SW620 1 μM 72 hours AT7519 inhibited the viability of mt KRas-dependent cells with IC50 value of 0.39 ± 0.06 μM PMC8493485
Calu6 1 μM 72 hours AT7519 inhibited the viability of mt KRas-dependent cells with IC50 value of 0.30 ± 0.05 μM PMC8493485
A549 1 μM 72 hours AT7519 inhibited the viability of mt KRas-independent cells with IC50 value of 3.71 ± 1.06 μM PMC8493485
H460 1 μM 72 hours AT7519 inhibited the viability of mt KRas-independent cells with IC50 value of 0.91 ± 0.10 μM PMC8493485
DLD1 1 μM 72 hours AT7519 inhibited the viability of mt KRas-independent cells with IC50 value of 5.95 ± 2.19 μM PMC8493485
HCT8 1 μM 72 hours AT7519 inhibited the viability of mt KRas-independent cells with IC50 value of 3.77 ± 1.1 μM PMC8493485
HEI-OC1 cells 0.380 μM 22 hours To evaluate the protective effect of AT7519 against cisplatin-induced cytotoxicity, results showed that AT7519 provided protection in HEI-OC1 cells with an EC50 of 0.380 μM. PMC6443376
P3 mouse cochlear explants 25 nM 24 hours To evaluate the protective effect of AT7519 against cisplatin-induced toxicity in cochlear explants, results showed that AT7519 provided significant protection at a concentration of 25 nM. PMC6443376
μM.1S 0.5 μM 6, 12, 24 hours AT7519 induces cell cycle arrest and apoptosis PMC3183744
U266 0.5 μM 48 hours AT7519 exhibits dose-dependent cytotoxicity PMC3183744
A375 melanoma cells 2 μM 3 hours To detect changes in MDM4 and p53 protein levels, results showed a decrease in MDM4 levels and p53 stabilization. PMC7494941

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice MYCN-amplified neuroblastoma xenograft model intraperitoneal injection 250 mg/kg Once daily for 4 weeks To evaluate the anti-tumor effect of AT7519 on MYCN-amplified neuroblastoma xenograft models, results showed that AT7519 significantly inhibited tumor growth in a dose-dependent manner PMC4645454
nude mice subcutaneous xenograft model intraperitoneal injection 20 mg/kg once daily for 12 days AT7519 significantly inhibited tumor growth in the subcutaneous xenograft model. PMC9829897
mice patient-derived xenograft models intraperitoneal injection 250 mg/kg 6 days/week for 13 days AT7519 suppressed tumor growth and in some cases caused tumor regression PMC8493485
Mice Human MM xenograft mouse model Intraperitoneal injection 20 mg/kg once daily for 3 weeks AT7519 inhibits tumor growth and prolongs survival PMC3183744

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01652144 Mantle Cell Lymphoma PHASE2 COMPLETED 2015-02-13 CancerCare Manitoba, Winnipeg,... More >> Manitoba, R3E 0V9, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, B3H 1V7, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|McGill University - Dept. Oncology, Montreal, Quebec, H2W 1S6, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada Less <<
NCT01627054 Chronic Lymphocytic Leukemia PHASE2 COMPLETED 2015-02-13 CancerCare Manitoba, Winnipeg,... More >> Manitoba, R3E 0V9, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.62mL

0.52mL

0.26mL

13.08mL

2.62mL

1.31mL

26.16mL

5.23mL

2.62mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories